IDH1 and IDH2 Gene Mutation Detection identifies mutations in the isocitrate dehydrogenase genes commonly associated with several hematologic and solid tumors, including acute myeloid leukemia (AML), gliomas, and cholangiocarcinoma. These mutations play a role in cancer development and are important diagnostic and prognostic markers. The test also aids in selecting targeted therapies, such as IDH inhibitors, which improve treatment outcomes. A blood sample collected in an EDTA tube is used for analysis by molecular methods
17 Crores+ Samples Processed
World Class Technology Labs
25+ Years of Trust & Experience
Free Home Collection
Price:
Rs. 6,825.00
Sample Type: EDTA BLOOD
Fasting Not Required
Notes: I0372
Frequently Asked Questions (FAQ's):
Why is the IDH1/IDH2 mutation test recommended?
It helps diagnose specific cancers, assess prognosis, and determine eligibility for targeted therapy.
Is fasting required before the test?
No fasting is required for this test.
How long does it take to receive results?
Typically 7–14 days, depending on the laboratory process.
Can this test guide treatment decisions?
Yes, the presence of IDH mutations may qualify patients for targeted IDH inhibitor therapies